Diaceutics offers data collaboration opportunities for co-locators at Dataworks headquarters in Belfast
London-listed diagnostic commercialization company Diaceutics has invited innovators in healthcare technology to collaborate with the company to advance new scientific discoveries at its new Precision Medicine hub, Dataworks. The new innovative hub is part of the Kings Hall Life Sciences in south Belfast.
Research groups, companies and healthcare organisations which choose to co-locate alongside Diaceutics or to work alongside its team of highly-qualified experts, will be able to gain access to the company’s Global Data Repository through a joint Data Collaboration Agreement. Amassed over the last decade, Diaceutics’ precision medicine diagnostic testing data repository unlocks unrivalled access to deep analysis of the world’s richest source of de-identified patient testing records incorporating over 300 million patient records and with 49 disease-specific treatment pathways (Diagnostic Deductive Pathways – DDPs) already mapped from this via accelerated algorithmic applications which are enabled by the company’s platform technology – DXRX.
Peter Keeling, Chief Executive Officer of Diaceutics, said: “The value of real-world data for precision medicine is now key to precision medicine commercialisation yet is so multidimensional that it requires collaboration to be fully realised, which is why we invite key stakeholders in the space to join us in exploring uses outside and adjacent to those we are applying today. We envisage Dataworks as a thriving and creative data hub of data analytics companies, medical professionals and patient centric groups collaborating in a shared space.
“At Dataworks, data analytics will live alongside a flow of patients and professionals, focused on understanding and improving patient health. The future of healthcare is data enabled, Dataworks has been designed with that in mind, I am convinced new learnings and innovations will arise from living alongside the front line of healthcare.”
Construction of Dataworks was recently completed and Diaceutics will move into the building this summer. It consists of smart office, laboratory, and shared space adjacent to the iconic Kings Hall building. The development will provide a secure and collaborative space for companies to focus on the rapidly growing and highly valuable healthcare data market.
Leveraging the smart city concept, Dataworks sits in direct proximity to healthcare professionals serving patients within the park and alongside Belfast’s major hospitals and universities and innovative medical research facilities.
The combination of a vibrant and entrepreneurial health community, a large talent pool of scientific minds and proximity to healthcare professionals treating patients, top universities such as Queen’s University Belfast and Ulster University makes Dataworks a new spatial model for life sciences companies.
The offer to collaborate is expected to become a significant draw for other precision medicine companies from around the world which will help to fulfil the ambition of Dataworks to become a fully collaborative space where knowledge, research and expertise can be shared to unlock the promise of precision medicine globally.
A further 30,000 square feet of medical and shared space has been available for lease within the Dataworks building alongside Diaceutics’ uniquely designed collaboration space. CBRE NI and Colliers are joint letting agent. When complete, the Kings Hall Health and Wellbeing Park will transform the provision of integrated healthcare in Northern Ireland by acting as a home for a range of health and medical service providers, alongside age exclusive and assisted living accommodation and as a base for a range of healthcare companies.
As well as Dataworks, the extended Kings Hall site – formerly the Balmoral showgrounds – will also include a range of age-appropriate living accommodation, a mixed-use medical facility, a multi-storey car park and childcare nursery Malone Kindergarten to support employees working in the park.
Planning permission for the next phase of development at the iconic site has just been granted by Belfast City Council and construction is expected to begin soon.
David Burrows, Director at Benmore Octopus, said: “Dataworks has already proven a draw for occupiers in the precision medicine space and we expect the generous offer from Diaceutics to be hugely attractive to companies from around the world. Building a community which can learn from each other, which can share knowledge and ultimately further advancement of precision medicine sits at the heart of the vision for Dataworks and we look forward to helping fulfil that aim in the very near future.”
Benmore Octopus is a joint venture between local developers Benmore Group and Octopus Real Estate.
L-R: Robert Ditty, Director at CBRE NI; David Burrows, Director at Benmore Octopus; Peter Keeling, Chief Executive Officer at Diaceutics and Ian Duddy, Director at Colliers.
DOWNLOAD THE FULL REPORT